News for Humacyte, Inc. (HUMA)

Humacyte's Symvess revolutionizes vascular trauma care with clinical benefits and growth potential.

Humacyte (HUMA) continues to hold a steady position in the stock market as noted by the latest analyst report from D. Boral Capital. Analyst Jason Kolbert has r

Humacyte (HUMA) has unveiled findings from its V007 Pivotal Phase 3 clinical trial, which demonstrated the performance of their acellular tissue-engineered vess

Humacyte's (HUMA) Phase 3 trial shows ATEV surpasses standard AVFs in high-risk dialysis patients. ATEV demonstrated better functional patency with fewe

Benefits of Humacyte's Acellular Tissue Engineered Vessel Over Autologous Arteriovenous Fistula (AVF) in High-Risk Patients with End-Stage Kidney Disease Obser

Humacyte markets Symvess for the treatment of extremity vascular trauma. Read why HUMA stock is a Sell but can see its utility in a barbell portfolio.

Humacyte (HUMA) has revealed that its research on the V007 Pivotal Phase 3 clinical trial, focusing on an acellular tissue-engineered vessel for arteriovenous a

AV Access Study to be Presented at the Vascular Annual Meeting (VAM25) DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. ( HUMA), a commercial-

The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Huma Finance pre-market trading offers investors a valuable opportunity to buy and sell HUMA tokens before they’re officially listed on exchanges. This early access trading window typically operates…

DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. ( HUMA), a commercial-stage biotechnology platform company developing universally implantable, b

**media[630798]**

H.C. Wainwright has initiated coverage on Humacyte (HUMA) with a Buy recommendation and set a price target of $4. The company's flagship product, Symvess, recei

On May 14, 2025, Benchmark analyst Bruce Jackson announced adjustments to Humacyte's (HUMA) stock price target. While maintaining the

Benchmark has adjusted its price target for Humacyte (HUMA), lowering it from $17 to $14 while maintaining a Buy rating on the stock. Despite this reduction, th

Revenue: $517,000 for Q1 2025, including $147,000 from the US commercial launch of Symvess.Cost of Goods Sold: $147,000 for Q1 2025.Research and Development Ex

May 13, 2025 / 12:30PM GMTOperator Good morning, ladies and gentlemen, and welcome to the Humacyte first quarter results conference call. (Operator Instructions

Summary: Humacyte, Inc. (HUMA) is focusing on the strategic roll-out of Symvess, particularly for extremity vascular trauma. The product gained traction

Discover how Humacyte, Inc. (HUMA) is advancing with its Symvess commercial launch, overcoming challenges, expanding hospital evaluations, and boosting...